Insider at Actuate Therapeutics Makes a Major Move With Fresh Stock Sale

New insider activity at Actuate Therapeutics, Inc. ( (ACTU) ) has taken place on January 7, 2026.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Director Todd Thomson has executed a significant sale of Actuate Therapeutics, Inc. stock, unloading 280,000 shares in a single transaction. The sale, totaling $1,624,000, represents a sizable move by an insider, and may draw attention from investors tracking director-level trading activity at Actuate Therapeutics, Inc. Recent Updates on ACTU stock Actuate Therapeutics, Inc. (ACTU) saw attention in the last 24 hours following new clinical updates on its lead candidate elraglusib, which could be key drivers behind any recent reassessments of the stock’s outlook and price targets. The company reported Phase 1 pediatric data showing complete metabolic and complete responses in highly refractory Ewing sarcoma and neuroblastoma patients, along with broader disease control in a meaningful subset of children treated, particularly in combination with cyclophosphamide/topotecan. These results, together with FDA Rare Pediatric Disease designations for both Ewing sarcoma and neuroblastoma, strengthen the perceived probability of future regulatory and commercial opportunities in rare pediatric oncology, a factor analysts typically weigh positively in valuation models. Separately, publication of Phase II data in Clinical Cancer Research for elraglusib plus platinum chemotherapy in advanced salivary gland cancers showed progression-free and overall survival outcomes that compare favorably with historical benchmarks, including durable responses in patients with low PD-L1 expression and poor-prognosis genomic co-deletions. This peer-reviewed validation of both efficacy and tolerability may lead analysts to revise assumptions about elraglusib’s addressable market, success odds, and duration of therapy, which in turn can underpin changes in sentiment and price expectations for ACTU shares, even if short-term price movements may also reflect typical volatility around early-stage biotech news rather than fundamentals alone. More about Actuate Therapeutics, Inc. YTD Price Performance: 8.82% Average Trading Volume: 76,075 Technical Sentiment Signal: Sell Current Market Cap: $147.4M